[ BiomX raises $24M in Series A ]
BiomX has raised $24 million in Series A funding.
Founded in 2015, BiomX discovers and develops innovative microbiome therapeutics. The Company’s mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated.
The new financing will be used to advance its novel therapeutic pipeline towards clinical stages and to continue enhancing its proprietary microbiome modulation platform technologies.
|Founder / CEO||Jonathan Solomon|
|SBI Japan-Israel Innovation Fund|
|Mirae Asset Venture Investment|
|Johnson & Johnson Innovation|